Biohaven Pharmaceutical Holding Company Ltd is a biotechnology business based in the US. Biohaven Pharmaceutical Holding Company shares (BHVN) are listed on the NYSE and all prices are listed in US Dollars. Biohaven Pharmaceutical Holding Company employs 825 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $118.77 |
|---|---|
| 52-week range | $62.57 - $151.51 |
| 50-day moving average | $119.65 |
| 200-day moving average | $113.19 |
| Wall St. target price | $154.91 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-13.70 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $118.77 from 2022-01-24
| 1 week (2022-01-19) | 3.24% |
|---|---|
| 1 month (2021-12-23) | -12.66% |
| 3 months (2021-10-26) | -16.02% |
| 6 months (2021-07-26) | -2.92% |
| 1 year (2021-01-26) | 33.78% |
|---|---|
| 2 years (2020-01-24) | 117.93% |
| 3 years (2019-01-25) | 231.39% |
| 5 years (2017-01-22) | N/A |
| Revenue TTM | $307.6 million |
|---|---|
| Gross profit TTM | $45.9 million |
| Return on assets TTM | -46.17% |
| Return on equity TTM | 0% |
| Profit margin | -281.25% |
| Book value | $2.09 |
| Market capitalisation | $7.8 billion |
TTM: trailing 12 months
We're not expecting Biohaven Pharmaceutical Holding Company to pay a dividend over the next 12 months.
Over the last 12 months, Biohaven Pharmaceutical Holding Company's shares have ranged in value from as little as $62.57 up to $151.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Biohaven Pharmaceutical Holding Company's is 1.0333. This would suggest that Biohaven Pharmaceutical Holding Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Biohaven Pharmaceutical Holding Company Ltd. , a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.